Basiliximab Maintenance in Ulcerative Colitis

PHASE2TerminatedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Ulcerative Colitis
Interventions
DRUG

Basiliximab

Study Drug: basiliximab 40 mg, given as a short intravenous infusion Dosing Schedule: once every 4 weeks Concomitant Therapy: Oral corticosteroids (prednisone or equivalent) will be tapered during the first few months of the study participation Duration of Study Participation: The duration of individual study participation will vary.

Trial Locations (1)

Unknown

Bristol

Sponsors
All Listed Sponsors
lead

Cerimon Pharmaceuticals

INDUSTRY